AU2016338637A1 - Combination antibacterial composition and short-course antibacterial regimen - Google Patents

Combination antibacterial composition and short-course antibacterial regimen Download PDF

Info

Publication number
AU2016338637A1
AU2016338637A1 AU2016338637A AU2016338637A AU2016338637A1 AU 2016338637 A1 AU2016338637 A1 AU 2016338637A1 AU 2016338637 A AU2016338637 A AU 2016338637A AU 2016338637 A AU2016338637 A AU 2016338637A AU 2016338637 A1 AU2016338637 A1 AU 2016338637A1
Authority
AU
Australia
Prior art keywords
months
treatment
administered
lzd
bdq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016338637A
Other languages
English (en)
Inventor
Khisimuzi Mdluli Jr.
Cari M. Mendel
Eric Nuermberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Alliance for TB Drug Development Inc
Original Assignee
Global Alliance for TB Drug Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58518568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016338637(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Global Alliance for TB Drug Development Inc filed Critical Global Alliance for TB Drug Development Inc
Publication of AU2016338637A1 publication Critical patent/AU2016338637A1/en
Priority to AU2021258039A priority Critical patent/AU2021258039B2/en
Priority to AU2024203012A priority patent/AU2024203012A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016338637A 2015-10-14 2016-10-05 Combination antibacterial composition and short-course antibacterial regimen Abandoned AU2016338637A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021258039A AU2021258039B2 (en) 2015-10-14 2021-10-28 Combination antibacterial composition and short-course antibacterial regimen
AU2024203012A AU2024203012A1 (en) 2015-10-14 2024-05-07 Combination antibacterial composition and short-course antibacterial regimen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241280P 2015-10-14 2015-10-14
US62/241,280 2015-10-14
PCT/US2016/055414 WO2017066053A1 (en) 2015-10-14 2016-10-05 Combination antibacterial composition and short-course antibacterial regimen

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021258039A Division AU2021258039B2 (en) 2015-10-14 2021-10-28 Combination antibacterial composition and short-course antibacterial regimen

Publications (1)

Publication Number Publication Date
AU2016338637A1 true AU2016338637A1 (en) 2018-04-26

Family

ID=58518568

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016338637A Abandoned AU2016338637A1 (en) 2015-10-14 2016-10-05 Combination antibacterial composition and short-course antibacterial regimen
AU2021258039A Active AU2021258039B2 (en) 2015-10-14 2021-10-28 Combination antibacterial composition and short-course antibacterial regimen
AU2024203012A Pending AU2024203012A1 (en) 2015-10-14 2024-05-07 Combination antibacterial composition and short-course antibacterial regimen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021258039A Active AU2021258039B2 (en) 2015-10-14 2021-10-28 Combination antibacterial composition and short-course antibacterial regimen
AU2024203012A Pending AU2024203012A1 (en) 2015-10-14 2024-05-07 Combination antibacterial composition and short-course antibacterial regimen

Country Status (14)

Country Link
US (3) US20180280401A1 (US20070167479A1-20070719-C00034.png)
EP (2) EP4324824A3 (US20070167479A1-20070719-C00034.png)
JP (4) JP6845233B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR20180063318A (US20070167479A1-20070719-C00034.png)
CN (2) CN108495631A (US20070167479A1-20070719-C00034.png)
AU (3) AU2016338637A1 (US20070167479A1-20070719-C00034.png)
BR (1) BR112018007625A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA3001309C (US20070167479A1-20070719-C00034.png)
EA (1) EA201890614A1 (US20070167479A1-20070719-C00034.png)
ES (1) ES2972618T3 (US20070167479A1-20070719-C00034.png)
HK (1) HK1254620A1 (US20070167479A1-20070719-C00034.png)
HR (1) HRP20240309T1 (US20070167479A1-20070719-C00034.png)
WO (1) WO2017066053A1 (US20070167479A1-20070719-C00034.png)
ZA (1) ZA201802236B (US20070167479A1-20070719-C00034.png)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108495631A (zh) * 2015-10-14 2018-09-04 结核病药物开发全球联盟公司 联合抗菌组合物以及短疗程抗菌方案
CN109387594B (zh) * 2017-08-08 2021-01-19 武汉武药科技有限公司 一种分离和分析贝达喹啉光学异构体的方法
BR112022000899A2 (pt) * 2019-07-19 2022-03-29 The Global Alliance For Tb Drug Dev Inc Composições de pretomanida
WO2021257461A1 (en) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Combination antibacterial composition and method for antibacterial therapy
GB202009684D0 (en) * 2020-06-26 2020-08-12 Viiv Healthcare Co Formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7889101B2 (en) * 2008-04-14 2011-02-15 Alpine Electronics, Inc Method and apparatus for generating location based reminder message for navigation system
CA2735229C (en) * 2008-09-03 2014-01-28 Pfizer Inc. Combination therapy for tuberculosis
WO2011139832A2 (en) * 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
CN108495631A (zh) * 2015-10-14 2018-09-04 结核病药物开发全球联盟公司 联合抗菌组合物以及短疗程抗菌方案

Also Published As

Publication number Publication date
WO2017066053A1 (en) 2017-04-20
AU2021258039A1 (en) 2021-11-25
AU2021258039B2 (en) 2024-02-08
JP2024053045A (ja) 2024-04-12
EP4324824A2 (en) 2024-02-21
JP2022082753A (ja) 2022-06-02
BR112018007625A2 (pt) 2018-10-30
US20230414625A1 (en) 2023-12-28
CA3001309C (en) 2023-12-19
JP6845233B2 (ja) 2021-03-17
JP2018530578A (ja) 2018-10-18
US20180280401A1 (en) 2018-10-04
EP4324824A3 (en) 2024-05-08
KR20180063318A (ko) 2018-06-11
HK1254620A1 (zh) 2019-07-26
ZA201802236B (en) 2022-07-27
US20200237770A1 (en) 2020-07-30
EP3362068A1 (en) 2018-08-22
CN114796231A (zh) 2022-07-29
AU2024203012A1 (en) 2024-05-23
HRP20240309T1 (hr) 2024-05-10
CN108495631A (zh) 2018-09-04
JP2021038257A (ja) 2021-03-11
EA201890614A1 (ru) 2019-02-28
EP3362068A4 (en) 2019-06-19
EP3362068C0 (en) 2023-12-20
EP3362068B1 (en) 2023-12-20
CA3001309A1 (en) 2017-04-20
ES2972618T3 (es) 2024-06-13
JP7221922B2 (ja) 2023-02-14

Similar Documents

Publication Publication Date Title
US20230414625A1 (en) Combination Antibacterial Composition and Short-Course Antibacterial Regimen
Savoia New antimicrobial approaches: reuse of old drugs
Protopopova et al. In search of new cures for tuberculosis
Gothi et al. Resistant TB: newer drugs and community approach
US20100197650A1 (en) Compositions and methods of treatment comprising ceftaroline
US10610563B2 (en) Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2
JP2015536949A (ja) 細菌感染症のための抗生物質を用いる方法および組成物
RU2593363C2 (ru) Композиции, включающие антибактериальное средство и тазобактам
Kotadiya et al. Recent advances in tuberculosis drug development
EP3331504A2 (en) Tablet composition for anti-tuberculosis antibiotics
WO2016020408A2 (en) Compounds for preventing ototoxicity
US11793816B2 (en) Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B
Kumar et al. Targeting Mycobacterium tuberculosis iron-scavenging tools: A recent update on siderophores inhibitors
EP4108244A1 (en) Ss-lactam antibiotic with significant activity against cancer e.g. colon malignancies
Akilandeswari et al. Studies on anti microbial potential of non-antibiotics on resistant bacteria-A Review
Semenya Recent Advances in Repositioning Non-Antibiotics against Tuberculosis and other Neglected Tropical Diseases
Ukwaja The Minimal Gene-Set Machinery
KR20110127219A (ko) 결핵 치료용 화합물
MA33080B1 (fr) Procede de preparation d'une composition pharmaceutique contenant en association la rifampicine, l'isoniazide, la pyrazinamide, et eventuellement l'ethambutol

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted